Reassessment of Reliability and Reproducibility for Triple-Negative Breast Cancer Subtyping
SIMPLE SUMMARY: Triple-negative breast cancer (TNBC) is a heterogeneous disease. A proper classification system is needed to develop targetable biomarkers and guide personalized treatment in clinical practice. However, there has been no consensus on the molecular subtypes of TNBC, probably due to di...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9179838/ https://www.ncbi.nlm.nih.gov/pubmed/35681552 http://dx.doi.org/10.3390/cancers14112571 |
_version_ | 1784723370101702656 |
---|---|
author | Yu, Xinjian Liu, Yongjing Chen, Ming |
author_facet | Yu, Xinjian Liu, Yongjing Chen, Ming |
author_sort | Yu, Xinjian |
collection | PubMed |
description | SIMPLE SUMMARY: Triple-negative breast cancer (TNBC) is a heterogeneous disease. A proper classification system is needed to develop targetable biomarkers and guide personalized treatment in clinical practice. However, there has been no consensus on the molecular subtypes of TNBC, probably due to discrepancies in technical and computational methods chosen by different research groups. In this paper, we reassessed each major step for TNBC subtyping and provided suggestions, which promote rational workflow design and ensure reliable and reproducible results for future studies. We presented a recommended pipeline to the existing data, validated established TNBC subtypes with a larger sample size, and revealed two intermediate subtypes with prognostic significance. This work provides perspectives on issues and limitations regarding TNBC subtyping, indicating promising directions for developing targeted therapy based on the molecular characteristics of each TNBC subtype. ABSTRACT: Triple-negative breast cancer (TNBC) is a heterogeneous disease with diverse, often poor prognoses and treatment responses. In order to identify targetable biomarkers and guide personalized care, scientists have developed multiple molecular classification systems for TNBC based on transcriptomic profiling. However, there is no consensus on the molecular subtypes of TNBC, likely due to discrepancies in technical and computational methods used by different research groups. Here, we reassessed the major steps for TNBC subtyping, validated the reproducibility of established TNBC subtypes, and identified two more subtypes with a larger sample size. By comparing results from different workflows, we demonstrated the limitations of formalin-fixed, paraffin-embedded samples, as well as batch effect removal across microarray platforms. We also refined the usage of computational tools for TNBC subtyping. Furthermore, we integrated high-quality multi-institutional TNBC datasets (discovery set: n = 457; validation set: n = 165). Performing unsupervised clustering on the discovery and validation sets independently, we validated four previously discovered subtypes: luminal androgen receptor, mesenchymal, immunomodulatory, and basal-like immunosuppressed. Additionally, we identified two potential intermediate states of TNBC tumors based on their resemblance with more than one well-characterized subtype. In summary, we addressed the issues and limitations of previous TNBC subtyping through comprehensive analyses. Our results promote the rational design of future subtyping studies and provide new insights into TNBC patient stratification. |
format | Online Article Text |
id | pubmed-9179838 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-91798382022-06-10 Reassessment of Reliability and Reproducibility for Triple-Negative Breast Cancer Subtyping Yu, Xinjian Liu, Yongjing Chen, Ming Cancers (Basel) Article SIMPLE SUMMARY: Triple-negative breast cancer (TNBC) is a heterogeneous disease. A proper classification system is needed to develop targetable biomarkers and guide personalized treatment in clinical practice. However, there has been no consensus on the molecular subtypes of TNBC, probably due to discrepancies in technical and computational methods chosen by different research groups. In this paper, we reassessed each major step for TNBC subtyping and provided suggestions, which promote rational workflow design and ensure reliable and reproducible results for future studies. We presented a recommended pipeline to the existing data, validated established TNBC subtypes with a larger sample size, and revealed two intermediate subtypes with prognostic significance. This work provides perspectives on issues and limitations regarding TNBC subtyping, indicating promising directions for developing targeted therapy based on the molecular characteristics of each TNBC subtype. ABSTRACT: Triple-negative breast cancer (TNBC) is a heterogeneous disease with diverse, often poor prognoses and treatment responses. In order to identify targetable biomarkers and guide personalized care, scientists have developed multiple molecular classification systems for TNBC based on transcriptomic profiling. However, there is no consensus on the molecular subtypes of TNBC, likely due to discrepancies in technical and computational methods used by different research groups. Here, we reassessed the major steps for TNBC subtyping, validated the reproducibility of established TNBC subtypes, and identified two more subtypes with a larger sample size. By comparing results from different workflows, we demonstrated the limitations of formalin-fixed, paraffin-embedded samples, as well as batch effect removal across microarray platforms. We also refined the usage of computational tools for TNBC subtyping. Furthermore, we integrated high-quality multi-institutional TNBC datasets (discovery set: n = 457; validation set: n = 165). Performing unsupervised clustering on the discovery and validation sets independently, we validated four previously discovered subtypes: luminal androgen receptor, mesenchymal, immunomodulatory, and basal-like immunosuppressed. Additionally, we identified two potential intermediate states of TNBC tumors based on their resemblance with more than one well-characterized subtype. In summary, we addressed the issues and limitations of previous TNBC subtyping through comprehensive analyses. Our results promote the rational design of future subtyping studies and provide new insights into TNBC patient stratification. MDPI 2022-05-24 /pmc/articles/PMC9179838/ /pubmed/35681552 http://dx.doi.org/10.3390/cancers14112571 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Yu, Xinjian Liu, Yongjing Chen, Ming Reassessment of Reliability and Reproducibility for Triple-Negative Breast Cancer Subtyping |
title | Reassessment of Reliability and Reproducibility for Triple-Negative Breast Cancer Subtyping |
title_full | Reassessment of Reliability and Reproducibility for Triple-Negative Breast Cancer Subtyping |
title_fullStr | Reassessment of Reliability and Reproducibility for Triple-Negative Breast Cancer Subtyping |
title_full_unstemmed | Reassessment of Reliability and Reproducibility for Triple-Negative Breast Cancer Subtyping |
title_short | Reassessment of Reliability and Reproducibility for Triple-Negative Breast Cancer Subtyping |
title_sort | reassessment of reliability and reproducibility for triple-negative breast cancer subtyping |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9179838/ https://www.ncbi.nlm.nih.gov/pubmed/35681552 http://dx.doi.org/10.3390/cancers14112571 |
work_keys_str_mv | AT yuxinjian reassessmentofreliabilityandreproducibilityfortriplenegativebreastcancersubtyping AT liuyongjing reassessmentofreliabilityandreproducibilityfortriplenegativebreastcancersubtyping AT chenming reassessmentofreliabilityandreproducibilityfortriplenegativebreastcancersubtyping |